Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 420 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Brain Imaging (PET) Clear all
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

NCT07348250
View directory record Official record
Conditions
Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
Interventions
[18F]MK-0947
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects

NCT01265394
View directory record Official record
Conditions
Healthy
Interventions
[18F] Flutemetamol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 40 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multi-modality Imaging Assessment of Chemobrain

NCT00708045
View directory record Official record
Conditions
Cancer
Interventions
[18F]fluoro-2-deoxy-D-glucose (FDG)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Results available

PET Imaging and Bariatric Surgery

NCT00801827
View directory record Official record
Conditions
Obesity, Morbid
Interventions
F-18 (fallypride)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 2, 2026, 6:50 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI

NCT04251130
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 2, 2026, 6:50 AM EDT
Recruiting Phase 2 Interventional

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

NCT07462507
View directory record Official record
Conditions
Central Nervous System Cancer, Brain Metastases
Interventions
[C-11]-CS1P1, Brain MRI
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 2, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Tau in Alzheimer's Disease and Normal Aging

NCT02884492
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
18F-THK-5351, Lumbar Puncture (optional)
Drug · Procedure
Lead sponsor
William Charles Kreisl
Other
Eligibility
50 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Single Photon Emission Computed Tomography (SPECT) Imaging Study of Professional American Football Players

NCT01515839
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Multivitamin Supplement intervention
Dietary Supplement
Lead sponsor
Amen Clinics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Not applicable Interventional Results available

FMISO PET Study of Glioblastoma

NCT02076152
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
FMISO PET, MRI, Bevacizumab, CCNU
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Nefazodone in the Treatment of Social Phobia

NCT00231348
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
Nefazodone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2013 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

NCT03545789
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
[18F]MNI-958
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 2, 2026, 6:50 AM EDT
Not listed Not applicable Interventional

Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain

NCT00087815
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Radiation Toxicity
Interventions
dexamethasone, hyperbaric oxygen, cognitive assessment, magnetic resonance imaging, positron emission tomography, quality-of-life assessment
Drug · Procedure
Lead sponsor
Barrett Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects

NCT03581305
View directory record Official record
Conditions
Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
Interventions
18F-FDOPA, 11C-DASB
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2

NCT00598286
View directory record Official record
Conditions
CB1, Cannabinoid, PET, Brain Imaging
Interventions
[18F]FMPEP-d2
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

Brain Reaction to Treatment of Nicotine Dependence

NCT00108173
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Zyban
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 60 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 2, 2026, 6:50 AM EDT
Approved For Marketing No phase listed Expanded access

Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study

NCT02355054
View directory record Official record
Conditions
Cancer of the Prostate
Interventions
C-11 Choline PET Imaging
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

NCT02079766
View directory record Official record
Conditions
Chronic Traumatic Encephalopathy
Interventions
florbetapir F 18, Flortaucipir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Male only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Phoenix, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2020 · Synced Sep 2, 2026, 6:50 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

NCT03539731
View directory record Official record
Conditions
Healthy Subject, Intracranial Neoplasm, Glioblastoma
Interventions
Fluorine F 18 DASA-23, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Guido A. Davidzon, MD, SM
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558

NCT01217021
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F] MNI-558
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Sep 2, 2026, 6:50 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Novel Positron Emission Tomography (PET Radiotracer for TARP Gamma-8

NCT02108015
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brain Imaging (PET), Aterial Line, Blood Sampling
Procedure
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

NCT00750282
View directory record Official record
Conditions
Alzheimer Disease, Amyloid Beta-Protein
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
55 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Sun City, Arizona • Stanford, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 2, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

NCT03289143
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Semorinemab, Placebo, [18F]GTP1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Birmingham, Alabama • Glendale, California • Irvine, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

NCT02531360
View directory record Official record
Conditions
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
Interventions
[18F]MNI-815 (MNI-815)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 2, 2026, 6:50 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

NCT03071224
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
[18F] MNI-946, [18F]Florbetapir
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 2, 2026, 6:50 AM EDT